Business
Re: Agreement
Re: Agreement.
About this update from Ixico Plc
[{"type":"text","content":"\n Phytopharm PLC\n09 January 2006\n\n\n\n PHYTOPHARM PLC AND SCHERING-PLOUGH ANIMAL HEALTH ENTER INTO A MARKETING AND \n DISTRIBUTION AGREEMENT FOR PHYTOPICA(TM)\n\nGODMANCHESTER, Cambridgeshire, U.K. (January 9th 2006) - Phytopharm plc (LSE:\nPYM; NASDAQBB: PHYOF; PHYOY) ('Phytopharm') announces today that it has entered\ninto an exclusive global marketing and distribution agreement with Schering-\nPlough Animal Health (Schering-Plough) for Phytopica(TM), a plant-based product\nclinically proven to promote healthy skin and coat in dogs. Phytopica(TM) is a\nnatural product combining the beneficial effects of 3 plants and provides a\nnovel 3 in 1 approach to help maintain a normal healthy immune system, support\nnormal white cell function and provide anti-oxidant benefits. Maintenance of a\nhealthy skin and coat condition are of major importance to canine general health\nand quality of life. Under the terms of the agreement, Phytopharm will be\nresponsible for the manufacture and sale of Phytopica(TM) to Schering-Plough.\nSchering-Plough will be responsible for the global sales, marketing and\ndistribution of Phytopica(TM).\n\nDr Richard Dixey, Chief Executive Officer of Phytopharm, said: 'We are delighted\nto enter this agreement with one of the world's leading animal health companies.\nPhytopica(TM) has already been introduced to veterinary dermatologists, and with\nSchering-Plough's global presence we look forward to maximizing the potential\nfor the product.'\n\n -ENDS-\n\n\nCompany Contact: U.K. Investor relations contact\nPhytopharm, plc Financial Dynamics\nRichard Dixey David Yates/Ben Atwell\n+44 7867 782000 +44 207 831 3113\nwww.phytopharm.com\n\n\nPHYTOPHARM PLC\nPhytopharm is focused on the research and development of novel pharmaceutical\nand functional food products based on clinical and pre-clinical data generated\nfrom medicinal plant extracts. The Company has seven development programmes in\nfour disease areas: neurodegeneration, obesity and metabolic disease,\ndermatology and inflammation and has a portfolio of two marketed veterinary\nproducts.\n\nMore information concerning Phytopharm's activities can be found on its web site\nat http://www.phytopharm.com\n\nThis press release may contain forward-looking statements within the meaning of\nSection 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S...